Whats Hot Today: Asterias Biotherapeutics (NYSEMKT:AST), Capnia (NASDAQ:CAPN), SunEdison (NYSE:SUNE), Oi SA (ADR) (NYSE:OIBR), Nektar Therapeutics (NASDAQ:NKTR)

On Friday shares of Asterias Biotherapeutics, Inc. (NYSEMKT:AST) closed at $7.47. Asterias Biotherapeutics, Inc. (NYSEMKT:AST)’s Pedro Lichtinger, President and Chief Executive Officer of Asterias, presented at the Regen Med Investor Day 2015 Conference at the Metropolitan Club in New York City on March 25, 2015 at 5:05 PM ET/2:05 PM PT.

Capnia, Inc. (NASDAQ:CAPN) in last trading activity increased 4.16% to close at $6.01. Company weekly performance is 11.92% while its quarterly performance stands at 257.74%. Capnia, Inc. (NASDAQ:CAPN) is -39.29% away from its 52 week high. Maxim Group initiated coverage on shares of Capnia Inc (NASDAQ:CAPN) in a research report sent to investors on Monday morning, TheFlyOnTheWall.com reports. The firm issued a buyrating and a $9.00 price target on the stock.

On Friday shares of SunEdison, Inc. (NYSE:SUNE) closed at $24.36. Company’s sales growth for last 5 years was 16.40% and EPS growth for next 5 years is recorded as 1.58%. SunEdison, Inc. has announced a partnership with the City of Long Beach to install four solar power plants for the City of Long Beach, according to a statement from SunEdison. The power plants will deliver a combined 2.5 megawatts of solar energy and are part of a call right list of TerraForm Power, Inc., a global owner and operator of clean energy power plants.

Oi SA (ADR) (NYSE:OIBR) in last trading activity moved up 2.27% to close at $1.80. Company weekly performance is -9.55%. Oi SA (ADR) (NYSE:OIBR) is -46.11% away from its 52 week high. Oi SA (ADR) (NYSE:OIBR) is working to improve cash flow, so capital spending this year will depend on how much cost cutting it can carry out, Chief Executive Bayard Gontijo told analysts on an earnings call on Friday.

On last trading day Nektar Therapeutics (NASDAQ:NKTR) increased 1.65% to close at $11.09. Its volatility for the week is 5.16% while volatility for the month is 4.79%. NKTR’s sales growth for past 5 years was 22.80% and its EPS growth for past 5 years was 17.70%. Nektar Therapeutics (NASDAQ:NKTR) monthly performance is -14.56%. On March 19, Nektar Therapeutics (NASDAQ: NKTR) reported that partner AstraZeneca announced a co-commercialisation agreement with Daiichi Sankyo, Inc. for MOVANTIK™ (naloxegol) in the US, in line with the Company’s strategy of delivering value through its own development and commercial capabilities as well as through external collaboration. MOVANTIK is a first-in-class once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.

Leave a Reply

Your email address will not be published. Required fields are marked *